Patents by Inventor Alissar Nehme

Alissar Nehme has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20190365786
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Application
    Filed: December 24, 2018
    Publication date: December 5, 2019
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 10493082
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 3, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Pharmaceutical compositions and methods of use of 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 10188667
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: January 29, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20180147217
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Application
    Filed: June 30, 2017
    Publication date: May 31, 2018
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • Pharmaceutical compositions and methods of use of 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 9717743
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: August 1, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20170182062
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Application
    Filed: August 4, 2016
    Publication date: June 29, 2017
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 9433631
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: September 6, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20150057258
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Application
    Filed: November 5, 2014
    Publication date: February 26, 2015
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20150005519
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Application
    Filed: September 12, 2014
    Publication date: January 1, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 8906892
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: December 9, 2014
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Pharmaceutical compositions and methods of use 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 8865691
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 21, 2014
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • TREATMENT OF TUMORS WITH ACETYLENES DISUBSTITUTED WITH A PHENYL OR HETEROAROMATIC GROUP AND A SUBSTITUTED CHROMANYL, THIOCHROMANYL OR TETRAHYDROQUINOLINYL GROUP IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
    Patent number: 6903121
    Abstract: Compounds of Formula 1 Formula 1 where the symbols have the meaning described in the specification, and particularly the compound of Formula 3 Formula 3 (tazarotene) exhibit synergistic anti-proliferative effect with human recombinant interferon in the treatment of solid tumors and leukemia, particularly breast cancer and acute myeloid leukemia.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: June 7, 2005
    Assignee: Allergan, Inc.
    Inventors: Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
  • Treatment of tumors with RAR&agr; selective retinoid compounds in combination with other anti-tumor agents
    Patent number: 6387950
    Abstract: Compounds which are specific or selective agonists of RAR&agr; receptors in preference over RAR&bgr; and RAR&ggr; receptors, and particularly compounds of the formula where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt, are useful for treating a malignant disease or condition in a mammal. In treatment of solid tumors the compound exhibit synergistic anti-proliferative effect with human recombinant interferon.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: May 14, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
  • Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
    Publication number: 20010039293
    Abstract: Compounds which are specific or selective agonists of RAR&agr; receptors in preference over RAR&bgr; and RAR&ggr; receptors, and particularly compounds of the formula 1
    Type: Application
    Filed: April 2, 2001
    Publication date: November 8, 2001
    Applicant: Allergan Sales, Inc.
    Inventors: Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna